{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:09:12Z","timestamp":1792030152858,"version":"4.4.0"},"reference-count":75,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T00:00:00Z","timestamp":1544659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004569","name":"Ministerstwo Nauki i Szkolnictwa Wy\u017cszego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Yeast"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>3\u2010Bromopyruvate (3<jats:sc>BP<\/jats:sc>) is a small, highly reactive molecule formed by bromination of pyruvate. In the year 2000, the antitumor properties of 3<jats:sc>BP<\/jats:sc> were discovered. Studies using animal models proved its high efficacy for anticancer therapy with no apparent side effects. This was also found to be the case in a limited number of cancer patients treated with 3<jats:sc>BP<\/jats:sc>. Due to the \u201cWarburg effect,\u201d most tumor cells exhibit metabolic changes, for example, increased glucose consumption and lactic acid production resulting from mitochondrial\u2010bound overexpressed hexokinase 2. Such alterations promote cell migration, immortality via inhibition of apoptosis, and less dependence on the availability of oxygen. Significantly, these attributes also make cancer cells more sensitive to agents, such as 3<jats:sc>BP<\/jats:sc> that inhibits energy production pathways without harming normal cells. This selectivity of 3<jats:sc>BP<\/jats:sc> is mainly due to overexpressed monocarboxylate transporters in cancer cells. Furthermore, 3<jats:sc>BP<\/jats:sc> is not a substrate for any pumps belonging to the ATP\u2010binding cassette superfamily, which confers resistance to a variety of drugs. Also, 3<jats:sc>BP<\/jats:sc> has the capacity to induce multiple forms of cell death, by, for example, ATP depletion resulting from inactivation of both glycolytic and mitochondrial energy production pathways. In addition to its anticancer property, 3<jats:sc>BP<\/jats:sc> also exhibits antimicrobial activity. Various species of microorganisms are characterized by different susceptibility to 3<jats:sc>BP<\/jats:sc> inhibition. Among tested strains, the most sensitive was found to be the pathogenic yeast\u2010like fungus <jats:styled-content style=\"fixed-case\"><jats:italic>Cryptococcus neoformans<\/jats:italic><\/jats:styled-content>. Significantly, studies carried out in our laboratories have shown that 3<jats:sc>BP<\/jats:sc> exhibits a remarkable capacity to eradicate cancer cells, fungi, and algae.<\/jats:p>","DOI":"10.1002\/yea.3367","type":"journal-article","created":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T19:54:20Z","timestamp":1542830060000},"page":"211-221","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["3\u2010Bromopyruvate as a potent anticancer therapy in honor and memory of the late Professor Andr\u00e9 Goffeau"],"prefix":"10.1002","volume":"36","author":[{"given":"Young H.","family":"Ko","sequence":"first","affiliation":[{"name":"KoDiscovery, LLC University of Maryland BioPark  Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Nied\u017awiecka","sequence":"additional","affiliation":[{"name":"Institute of Genetics and Microbiology University of Wroc\u0142aw  Wroc\u0142aw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Casal","sequence":"additional","affiliation":[{"name":"Centre of Molecular and Environmental Biology (CBMA), Department of Biology University of Minho  Braga Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry and Oncology, Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine  Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4736-3717","authenticated-orcid":false,"given":"Stanis\u0142aw","family":"U\u0142aszewski","sequence":"additional","affiliation":[{"name":"Institute of Genetics and Microbiology University of Wroc\u0142aw  Wroc\u0142aw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,12,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10863-016-9670-z"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20140921"},{"key":"e_1_2_9_4_1","first-page":"3654","article-title":"Glucose catabolism in African trypanosomes","volume":"268","author":"Barnard J. P.","year":"1993","journal-title":"The Journal of Biological Chemistry"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.206714"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-008-0688-8"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2018.03.104"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/176532"},{"issue":"14343","key":"e_1_2_9_10_1","article-title":"The energy blockers bromopyruvate and lonidamine lead GL15 glioblastoma cells to death by different p53\u2010dependent routes","volume":"5","author":"Davidescu M.","year":"2015","journal-title":"Scientific Reports"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299529"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S122241"},{"key":"e_1_2_9_13_1","unstructured":"Dyl\u0105g M. Lis P. Ko Y. H. Pedersen P. L. Goffeau A. &U\u0142aszewski S.(2012).Use of the composition of 3\u2010bromopyruvate as a second application of a medicament for the treatment of fungal infections. Patent No. 219802."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2013.02.125"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2017.01.014"},{"key":"e_1_2_9_16_1","first-page":"356","article-title":"Safety and outcome of treatment of metastatic melanoma using 3\u2010bromopyruvate: A concise literature review and case study","volume":"33","author":"El Sayed S. M.","year":"2014","journal-title":"Chinese Journal of Cancer"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10863-012-9455-y"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.174"},{"key":"e_1_2_9_19_1","first-page":"13","article-title":"Anticancer efficacy of the metabolic blocker 3\u2010bromopyruvate: Specific molecular targeting","volume":"33","author":"Ganapathy\u2010Kanniappan S.","year":"2013","journal-title":"Anticancer Research"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1039\/C3MT00191A"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39608"},{"key":"e_1_2_9_22_1","first-page":"470","article-title":"The diagnosis and treatment of multiple myeloma","volume":"113","author":"Gerecke C.","year":"2016","journal-title":"Deutsches \u00c4rzteblatt International"},{"key":"e_1_2_9_23_1","first-page":"3909","article-title":"Novel therapy for liver cancer: Direct intraarterial injection of a potent inhibitor","volume":"62","author":"Geschwind J. F.","year":"2002","journal-title":"Cancer Research"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2014.08.066"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2120"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2015.06.001"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00375"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(14)70245-X"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2015.10.101"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10863-008-9188-0"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(01)00667-X"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.09.047"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10863-012-9417-4"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10863-015-9637-5"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.60"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.22525"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174271"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.11.6509"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules21121730"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7174"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10863-012-9421-8"},{"key":"e_1_2_9_45_1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/CAD.0000000000000094","article-title":"Killing multiple myeloma cells with the small molecule 3\u2010bromopyruvate: Implications for therapy","volume":"25","author":"Majkowska\u2010Skrobek G.","year":"2014","journal-title":"Anti\u2010Cancer Drugs"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209603"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2008.11.006"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1006\/excr.2000.4834"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027222"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11592"},{"key":"e_1_2_9_51_1","first-page":"525","article-title":"New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the International Myeloma Working Group (IMWG)","volume":"28","author":"Ocio E.","year":"2014","journal-title":"Leucemia"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1925"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1159\/000401202"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10863-012-9425-4"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20080805"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13537"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-568899"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12790"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-005-6075-6"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.10160"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.2478\/s11658-014-0189-1"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2015.11.007"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-9-19"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21166"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14304"},{"key":"e_1_2_9_66_1","unstructured":"Stewart B. D. &Wild C. P.(2014).World Cancer Report 2014.World Health Organization.doi.org\/9283204298"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10863-015-9612-1"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24532"},{"key":"e_1_2_9_69_1","volume-title":"Metabolic parameters involved in keloid scar formation","author":"Vincent A.","year":"2009"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.098830"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.22007"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115141"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.01.149"},{"key":"e_1_2_9_74_1","first-page":"10746","article-title":"Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting","volume":"8","author":"Zhang K.","year":"2016","journal-title":"Oncotarget"},{"key":"e_1_2_9_75_1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.18632\/genesandcancer.9","article-title":"Hexokinase II inhibitor, 3\u2010BrPA induced autophagy by stimulating ROS formation in human breast cancer cells","volume":"5","author":"Zhang Q.","year":"2014","journal-title":"Genes & Cancer"},{"key":"e_1_2_9_76_1","first-page":"GW25","article-title":"3\u2010Bromopyruvate prevents monocrotaline\u2010induced pulmonary arterial hypertension in rats","volume":"189","author":"Zhang R.","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"}],"container-title":["Yeast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fyea.3367","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/yea.3367","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/yea.3367","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/yea.3367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T20:53:47Z","timestamp":1694379227000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/yea.3367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,13]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1002\/yea.3367"],"URL":"https:\/\/doi.org\/10.1002\/yea.3367","archive":["Portico"],"relation":{},"ISSN":["0749-503X","1097-0061"],"issn-type":[{"value":"0749-503X","type":"print"},{"value":"1097-0061","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,13]]},"assertion":[{"value":"2018-08-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}